Soligenix Inc
Change company Symbol lookup
Select an option...
SNGX Soligenix Inc
HON Honeywell International Inc
AXP American Express Co
PNGAY Ping An Insurance Group Co of China Ltd
YRIV Yangtze River Port and Logistics Ltd
PINVF Pinnacle Investment Management Group Ltd
PNFPP Pinnacle Financial Partners Inc
KGHZF Pangolin Diamonds Corp
PUCCF Pancontinental Resources Corporation
PCOGF Pancontinental Oil & Gas NL
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two business segments: Specialized BioTherapeutics and Public Health Solution. Soligenix’s Specialized BioTherapeutics business segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma (CTCL). The Public Health Solutions business segment includes active development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious disease. CTCL is its innate defense regulator technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Closing Price
$0.9646
Day's Change
-0.0194 (-1.97%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.988
Day's Low
0.9425
Volume
(Below Average)
Volume:
257,052

10-day average volume:
306,318
257,052

Company Profile

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two business segments: Specialized BioTherapeutics and Public Health Solution. Soligenix’s Specialized BioTherapeutics business segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma (CTCL). The Public Health Solutions business segment includes active development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious disease. CTCL is its innate defense regulator technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
24.43x
Price/Book (MRQ)
2.23x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

June 2021
Current Month
953.3K
Previous Month
953.6K
Percent of Float
2.45%
Days to Cover
2.8345 Days

Share Information

SNGX is in a share class of common stock
Float
38.9M
Shares Outstanding
40.1M
Institutions Holding Shares
34
9.88%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Christopher J. SchaberChmn.
  • Jonathan L. GuarinoCFO
  • Oreola DoniniSr.VP
  • Richard C. StraubeSr.VP
  • Gregg A. Lapointe

Address

Insider Trading

During the most recent quarter, 3K shares were bought, and 3K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.